Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Third Rock Ventures

Third Rock Ventures

Third Rock Ventures is a venture capital firm based in Boston, founded in 2007, which invests in biotechnology startups.

Third Rock Ventures is a venture capital firm headquartered in Boston, Massachusetts. The firm was established by Kevin Starr, Mark Levin, and Robert Tepper in 2007. As of July 2019, Third Rock Ventures is managing an active portfolio of 34 companies and has sold off its ownership in 57 companies. The firm specializes in funding companies at the early stage of development, in the field of biotechnology. Third Rock ventures provided venture capital to MyoKardia, a company which focuses on genetic heart diseases, that went public in 2015.

Timeline

October 31, 2016
Third Rock announces $616m Fund IV

Invested in

Associated investment funds

Patents

Funding Rounds Participated In

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

News

Title
Author
Date
Publisher
Description
BioSpace
June 23, 2021
BioSpace
Third Rock Ventures today announced the launch of Abata Therapeutics.
Alex Keown
June 23, 2021
BioSpace
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.
BioSpace
June 14, 2021
BioSpace
Asher Biotherapeutics today announced the formation of its Scientific Advisory Board, with the appointment of five leading scientists in the fields of immunology, oncology and protein therapeutics.
May 13, 2021
BioSpace
Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors - read this article along with other careers information, tips and advice on BioSpace
Melanie Senior
April 1, 2021
Nature Biotechnology
Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.